CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
TLC399 (ProDex)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03093701
NCT03093701Phase 2Completed
CompareCT.gov

TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

Taiwan Liposome Company·interventional·Posted Mar 28, 2017·Updated Dec 23, 2021

In Brief

A Phase 2 clinical trial evaluating TLC399 (ProDex) for Retinal Vein Occlusion and Macula Edema. Completed, enrolled 31 participants across 20 sites.

Detailed Summary

Randomized, double-masked trial designed to investigate the use of TLC399 (ProDex) in subjects with macular edema due to CRVO or BRVO.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRetinal Vein Occlusion, Macula Edema
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 28, 2017
Enrollment StartApr 1, 2017
Primary CompletionFeb 4, 2019
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 9.3 years ago

Interventions

TLC399 (ProDex)drug

2-vial system: TLC399-DSP and TLC399-Lipid